Swiss Medica, Inc.

Swiss Medica, Inc.

June 02, 2005 06:00 ET

Swiss Medica And National Fibromyalgia Association Schedule Joint Announcement Of New Breakthrough Pain Relief Treatment For Fibromyalgia Sufferers

TORONTO, ONTARIO--(CCNMatthews - June 2, 2005) - Swiss Medica Inc. (OTCBB:SWME) will host a joint press announcement with the National Fibromyalgia Association (NFA) on June 6, 2005 at the National Association of Chain Drug Stores (NACDS) Marketplace conference in New Orleans to unveil a new strategic partnership - and officially launch O24 Fibromyalgia pain reliever. O24 Fibromyalgia is the first product of its kind developed to specifically address the symptoms of chronic pain associated with the fibromyalgia syndrome and is also a patented and clinically tested, strong and safe, all-natural, over-the-counter health product. Swiss Medica is the owner and distributor of this product.

Lynne Matallana, the founder and president of the NFA, will speak at a press conference about the plight of up to 11 million Americans living with the chronic pain caused by fibromyalgia - and how Swiss Medica's new O24 Fibromyalgia pain reliever will become the first product to carry the NFA official Seal of Approval on its packaging. Swiss Medica President, Grant Johnson will discuss the previously announced results of a recently completed randomized double blind clinical trial that compared the O24 pain reliever against a placebo on patients suffering fibromyalgia.

Fibromyalgia is typically characterized by widespread musculoskeletal aches, pain and stiffness, soft tissue tenderness, general fatigue and sleep disturbances. The most common sites of pain include the neck, back, shoulders, pelvic girdle and hands. Fibromyalgia patients experience a range of symptoms, varying in intensity that can fluctuate over time.

The NFA estimates that the average family doctor sees at least one patient each day who is suffering from fibromyalgia and that the syndrome could be costing the U.S. economy as much as $10 billion a year in lost productivity.

Ms. Matallana and Mr. Johnson will also discuss the launch of the new O24 Fibromyalgia product in pharmacies throughout the United States and Canada. Swiss Medica's O24 Essential Oil Pain Neutralizer will be available in over 13,000 stores throughout North America by the end of June 2005.

About the National Fibromyalgia Association

The National Fibromyalgia Association (previously known as the National Fibromyalgia Awareness Campaign) is a (501(C) 3) nonprofit organization whose mission is: To develop and execute programs dedicated to improving the quality of life for people with Fibromyalgia by increasing the awareness of the public, media, government and medical communities. The NFA is committed to efforts that will increase FM awareness and improve treatment options for people with Fibromyalgia. With teamwork and dedication, the NFA will continue to grow into a key organization helping people with FM everywhere.

About Swiss Medica Inc.

Swiss Medica commercializes proprietary bioscience products that relieve chronic ailments. We increase our market share through focused distribution strategies in multiple sales channels. Swiss Medica's mission is to be a world leader in the commercialization of life enhancing bioscience products that improve quality of lives. Please visit our websites at, and

Swiss Medica's flagship product, the O24 Essential Oil Pain Neutralizer, holds US Patent #6,444,238B1. The O24 pain relief solution has been used, recommended and praised for its fast-acting and long-lasting benefits by healthcare professionals in the United States, Canada and in Europe. O24 is widely available throughout Canada in leading pharmacies and natural food stores. It is currently sold in an increasing number of pharmacies throughout the United States. Customers can also visit, for ordering details and store locators for the nearest pharmacy.

Swiss Medica also manufactures PMSEscape which holds US Patent #'s 5760014 and 5612320. PMSEscape is a specially formulated group of carbohydrates, vitamins and minerals, clinically proven to reduce changes in mood and appetite that women experience during the premenstrual period. Customers can also visit for additional information and ordering details.

Forward-looking statements in this news release are made pursuant to the "Safe Harbor" provisions of the United States Private Securities Litigation Reform Act of 1995. Investors are cautioned that such forward-looking statements involve risks and uncertainties, including, without limitation, risks relating to the ability to close transactions being contemplated, risks related to international sales and potential foreign currency exchange fluctuations, continued acceptance of Swiss Medica's products, increased levels of competition, technological changes, dependence on intellectual property rights and other risks detailed from time to time in Swiss Medica's periodic reports filed with the United States Securities and Exchange Commission and other regulatory authorities.

Contact Information